Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease(Version 2024)  

作　　者：Jian-Gao Fan Xiao-Yuan Xu Rui-Xu Yang Yue-Min Nan Lai Wei Ji-Dong Jia Hui Zhuang Jun-Ping Shi Xiao-Ying Li Chao Sun Jie Li Vincent Wai-Sun Wong Zhong-Ping Duan Chinese Society of Hepatology,Chinese Medical Association 

机构地区：[1]Department of Gastroenterology,Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai,China [2]Department of Infectious Diseases,Peking University First Hospital,Beijing,China [3]Department of Traditional and Western Medical Hepatology,Hebei Medical University Third Hospital,Shijiazhuang,Hebei,China [4]Hepatopancreatobiliary Centre,Beijing Tsinghua Changgung Hospital,Tsinghua University,Beijing,China [5]Liver Research Centre,Beijing Friendship Hospital,Capital Medical University,Beijing,China [6]Department of Microbiology and Centre for Infectious Diseases,Peking University Health Science Centre,Beijing,China [7]Department of Hepatology,The Affiliated Hospital of Hangzhou Normal University,Hangzhou,Zhejiang,China [8]Department of Endocrinology and Metabolism,Zhongshan Hospital,Fudan University,Shanghai,China [9]Department of Infectious Disease,Nanjing Drum Tower Hospital,Affiliated Hospital of Medical School,Nanjing University,Nanjing,Jiangsu,China [10]State Key Laboratory of Digestive Disease,Institute of Digestive Disease,The Chinese University of Hong Kong,Hong Kong,China [11]Fourth Department of Liver Disease,Beijing Youan Hospital,Capital Medical University,Beijing,China [12]不详

出　　处：《Journal of Clinical and Translational Hepatology》2024年第11期955-974,共20页临床与转化肝病杂志（英文版）

基　　金：supported by the National Science and Technology Major Project of China(No:2023ZD0508700).

摘　　要：With the rising epidemic of obesity,metabolic syndrome,and type 2 diabetes mellitus in China,metabolic dysfunctionassociated non-alcoholic fatty liver disease has become the most prevalent chronic liver disease.This condition frequently occurs in Chinese patients with alcoholic liver disease and chronic hepatitis B.To address the impending public health crisis of non-alcoholic fatty liver disease and its underlying metabolic issues,the Chinese Society of Hepatology and the Chinese Medical Association convened a panel of clinical experts to revise and update the“Guideline of prevention and treatment of non-alcoholic fatty liver disease(2018,China)”.The new edition,titled“Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease(Version 2024)”,offers comprehensive recommendations on key clinical issues,including screening and monitoring,diagnosis and evaluation,treatment,and followup for metabolic dysfunction-associated fatty liver disease and metabolic dysfunction-associated steatotic liver disease.Metabolic dysfunction-associated fatty liver disease is now the preferred English term and is used interchangeably with metabolic dysfunction-associated steatotic liver disease.Additionally,the guideline emphasizes the importance of multidisciplinary collaboration among hepatologists and other specialists to manage cardiometabolic disorders and liver disease effectively.

关 键 词：Non-alcoholic fatty liver disease Metabolic dysfunction-associated fatty liver disease Metabolic dysfunction-associated steatotic liver disease Type 2 diabetes mellitus Cardiovascular disease Management GUIDELINE 

分 类 号：R575.5[医药卫生—消化系统]